Cellebrite DI (NASDAQ:CLBT) Price Target Raised to $23.00

Cellebrite DI (NASDAQ:CLBT) had its target price raised by equities research analysts at Lake Street Capital from $22.00 to $23.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective indicates a potential upside of 20.14% from the company’s previous close.

CLBT has been the subject of a number of other reports. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Bank of America raised their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, November 7th. Finally, Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Cellebrite DI Stock Up 19.9%

CLBT stock traded up $3.18 during midday trading on Thursday, hitting $19.15. The company’s stock had a trading volume of 3,158,082 shares, compared to its average volume of 1,638,035. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of -25.26, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28. Cellebrite DI has a 12 month low of $13.10 and a 12 month high of $26.30. The company has a 50 day moving average of $17.72 and a two-hundred day moving average of $16.69.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million for the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.14 EPS. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Several institutional investors and hedge funds have recently made changes to their positions in the company. Financial Management Professionals Inc. purchased a new position in Cellebrite DI during the 3rd quarter valued at about $28,000. CWM LLC boosted its stake in shares of Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after purchasing an additional 720 shares in the last quarter. Assetmark Inc. purchased a new position in Cellebrite DI during the first quarter valued at approximately $33,000. Signaturefd LLC raised its stake in Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares in the last quarter. Finally, Toth Financial Advisory Corp purchased a new stake in Cellebrite DI during the third quarter worth $38,000. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.